Condition: Neuroendocrine Tumors,Gastroenteropancreatic · Sponsor: National Health Research Institutes, Taiwan
This is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of small molecule kinase inhibitor or well-differentiated (W-D) G3 GEP-NET who failed to one line of small molecule kinase inhibitor or chemotherapy.
This description comes directly from the study's public registry record.
Ya-Ling Wu, BS · 886-3-7206166 · yalin@nhri.edu.tw
Hui-Jen Tsai, PhD · 886-6-2353535 · hjtsai@nhri.org.tw
Always discuss trial participation with your own doctor first.
| Changhua Christian Hospital | Changhua, Taiwan | Recruiting |
| Chang Gung Medical Foundation | Kaohsiung City, Taiwan | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Recruiting |
| China Medical University Hospital | Taichung, Taiwan | Recruiting |
| Taichung Veterans General Hospital | Taichung, Taiwan | Recruiting |
| National Cheng Kung University Hospita | Tainan, Taiwan | Recruiting |
| Mackay Memorial Hospital | Taipei, Taiwan | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan | Recruiting |
| Tri-Service General Hospital | Taipei, Taiwan | Recruiting |
| Chang Gung Medical Foundation | Taoyuan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05048901